Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorasidenib in Advanced Hematologic Malignancies
NCT02492737Phase 1Completed
- Sponsor
- Agios Pharmaceuticals
- Start
- Aug 2015
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of vorasidenib in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and hematologic malignancy, sponsored by Agios Pharmaceuticals. Primary endpoints: Incidence of adverse events up to 26 weeks and Maximum Tolerated Dose and/or Recommended Phase II Dose up to 26 weeks. Started Aug 2015; status: completed.
02
Drugs
vorasidenib
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)hematologic malignancy
Beyond the preview
Go deeper on NCT02492737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02492737.